Dr. Ribas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
100 Med Plz
Ste 550
Los Angeles, CA 90095
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1998 - 2001
- Universidad de Barcelona Faculty of MedicineClass of 1990
Certifications & Licensure
- CA State Medical License 2001 - 2025
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2009
Clinical Trials
- ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma Start of enrollment: 2004 Feb 01
- CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery Start of enrollment: 2004 Apr 01
- Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy Start of enrollment: 2004 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 3231 citationsPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A. Wargo, Antoni Ribas
Cell. 2017-02-09 - 3890 citationsCancer immunotherapy using checkpoint blockadeAntoni Ribas
Science. 2018-03-23 - 48 citationsIntegrative Tumor and Immune Cell Multi-omic Analyses Predict Response to Immune Checkpoint Blockade in MelanomaValsamo Anagnostou, Daniel C. Bruhm, Noushin Niknafs, James R. White, Xiaoshan M. Shao
Cell Reports. Medicine. 2020-11-17
Journal Articles
- Isolation and Characterization of NY-ESO-1–Specific T Cell Receptors Restricted on Various MHC MoleculesAntoni Ribas, Proceedings of the National Academy of Sciences
- Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based ImmunotherapyJonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
- Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human CancersAntoni Ribas, Jennifer A Wargo, Sumit K Subudhi, Padmanee Sharma, Clinical Cancer Research
- Join now to see all
Lectures
- Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-Treated Patients with BRAFV600-Mutated Metastatic MelanomaInternational Society for Biological Therapy of Cancer (iSBTc)/ Society for Immunotherapy of Cancer, - 10/24/2012
- International Society for Biological Therapy of Cancer (iSBTc): Annual MeetingInternational Society for Biological Therapy of Cancer (iSBTc)/ Society for Immunotherapy of Cancer, - 10/26/2012
Authored Content
- Outcomes by Line of Therapy and Programmed Death Ligand 1 Expression in Patients with Advanced Melanoma Treated with Pembrolizumab or Ipilimumab in KEYNOTE-006: A Randomised Clinical TrialAugust 2018
Press Mentions
- UCLA and Parker Institute Continue Collaboration to Advance Next-Generation Cancer ImmunotherapiesOctober 16th, 2024
- Cancer Spread to Jimmy Carter's Brain 9 Years Ago. Here's How He's Lived so LongSeptember 30th, 2024
- Cancer Treatment Extended Jimmy Carter’s Life Before His 100th BirthdaySeptember 30th, 2024
- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: